DNLI short interest
Denali Therapeutics Inc. · Healthcare · Biotechnology · settlement date 2026-09-30
| Shares short | 15,463,975 |
|---|---|
| Change vs prior report | -1,675,440 (-9.8%) |
| Change over six months | +0.3% |
| Days to cover | 7.64 (sector: 3.78) |
| Average daily volume | 2,023,714 |
| Rank in Healthcare | #209 of 922 by days to cover |
DNLI short interest, last 12 months
| Settlement | Shares short | Change | Days to cover | Avg daily volume |
|---|---|---|---|---|
| 2026-09-30 | 15,463,975 | -9.8% | 7.64 | 2,023,714 |
| 2026-09-15 | 17,139,415 | +3.0% | 11.97 | 1,431,794 |
| 2026-08-31 | 16,642,362 | -7.3% | 17.50 | 951,216 |
| 2026-08-14 | 17,959,465 | +3.0% | 12.41 | 1,446,971 |
| 2026-07-31 | 17,434,654 | +8.7% | 12.12 | 1,438,878 |
| 2026-07-15 | 16,035,916 | +0.5% | 8.39 | 1,910,758 |
| 2026-06-30 | 15,949,089 | +3.5% | 6.95 | 2,295,382 |
| 2026-06-15 | 15,407,744 | +2.8% | 8.43 | 1,827,145 |
| 2026-05-29 | 14,990,471 | +6.9% | 8.02 | 1,870,118 |
| 2026-05-15 | 14,026,925 | -5.3% | 7.51 | 1,867,525 |
| 2026-04-30 | 14,813,936 | -3.1% | 9.95 | 1,488,830 |
| 2026-04-15 | 15,284,401 | -0.9% | 11.04 | 1,384,899 |
| 2026-03-31 | 15,421,152 | +8.2% | 6.67 | 2,313,194 |
| 2026-03-13 | 14,258,580 | -0.4% | 9.53 | 1,496,161 |
| 2026-02-27 | 14,319,419 | +5.3% | 9.03 | 1,586,528 |
| 2026-02-13 | 13,594,971 | +0.3% | 8.71 | 1,560,915 |
| 2026-01-30 | 13,558,718 | -8.8% | 7.02 | 1,931,940 |
| 2026-01-15 | 14,858,586 | +2.0% | 9.68 | 1,535,667 |
| 2025-12-31 | 14,560,677 | +11.2% | 12.46 | 1,168,804 |
| 2025-12-15 | 13,092,563 | +0.9% | 6.15 | 2,129,587 |
| 2025-11-28 | 12,977,218 | -7.4% | 10.05 | 1,291,586 |
| 2025-11-14 | 14,017,386 | +6.9% | 9.06 | 1,547,313 |
| 2025-10-31 | 13,110,288 | -9.8% | 8.85 | 1,481,293 |
| 2025-10-15 | 14,527,782 | +2.7% | 8.52 | 1,705,495 |
| 2025-09-30 | 14,150,041 | +8.2% | 5.69 | 2,488,560 |
import finzdata as yf
yf.Ticker("DNLI").short_interest # every report since 2017
yf.Client().short_interest(["DNLI"], start="2018-01-01")Healthcare short interest · DNLI price history · Who owns DNLI · All short interest